Acrylamide-encapsulated glucose oxidase inhibits breast cancer cell viability

dc.authoridÖykü Gönül Geyik / 0000-0003-3014-1253en_US
dc.authorscopusidÖykü Gönül Geyik / 56695248800
dc.authorwosidÖykü Gönül Geyik / AHB-4716-2022
dc.contributor.authorRrustemi, Trendelina
dc.contributor.authorGönül Geyik, Öykü
dc.contributor.authorÖzkaya, Ali Burak
dc.contributor.authorÖztürk, Taylan Kurtuluş
dc.contributor.authorYüce, Zeynep
dc.contributor.authorKılınç, Ali
dc.date.accessioned2021-01-22T08:34:15Z
dc.date.available2021-01-22T08:34:15Z
dc.date.issued2020en_US
dc.departmentİstinye Üniversitesi, Sağlık Bilimleri Fakültesi, Beslenme ve Diyetetik Bölümüen_US
dc.description.abstractObjectives: Cancer cells modulate metabolic pathways to ensure continuity of energy, macromolecules and redoxhomeostasis. Although these vulnerabilities are often targeted individually, targeting all with an enzyme may prove a novel approach. However, therapeutic enzymes are prone to proteolytic degradation and neutralizing antibodies leading to a reduced half-life and effectiveness. We hypothesized that glucose oxidase (GOX) enzyme that catalyzes oxidation of glucose and production of hydrogen peroxide, may hit all these targets by depleting glucose; crippling anabolic pathways and producing reactive oxygen species (ROS); unbalancing redox homeostasis. Methods: We encapsulated GOX in an acrylamide layer and then performed activity assays in denaturizing settings to determine protection provided by encapsulation. Afterwards, we tested the effects of encapsulated (enGOX) and free (fGOX) enzyme on MCF-7 breast cancer cells. Results: GOX preserved 70% of its activity following encapsulation. When fGOX and enGOX treated with guanidinium chloride, fGOX lost approximately 72% of its activity, while enGOX only lost 30%. Both forms demonstrated remarkable resilience against degradation by proteinase K and inhibited viability of MCF-7 cells in an activity-dependent manner. Conclusions: Encapsulation provided protection to GOX against denaturation without reducing its activity, which would prolong half-life of the enzyme when administered intravenously.en_US
dc.identifier.citationRrustemi, T., Geyik, Ö. G., Özkaya, A. B., Öztürk, T. K., Yüce, Z., & Kılınç, A. (2020). Acrylamide-encapsulated glucose oxidase inhibits breast cancer cell viability. Turkish Journal of Biochemistry, 1(ahead-of-print).en_US
dc.identifier.doi10.1515/tjb-2020-0247en_US
dc.identifier.endpage816en_US
dc.identifier.issn0250-4685en_US
dc.identifier.issn1303-829Xen_US
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85098995566en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage811en_US
dc.identifier.urihttps://doi.org/10.1515/tjb-2020-0247
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1358
dc.identifier.volume45en_US
dc.identifier.wosWOS:000603517600022en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.institutionauthorGönül Geyik, Öykü
dc.language.isoenen_US
dc.publisherWALTER DE GRUYTER GMBHen_US
dc.relation.ispartofTURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISIen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBiocompatibilityen_US
dc.subjectCancer Therapyen_US
dc.subjectGlucose Oxidaseen_US
dc.subjectMCF-7en_US
dc.subjectSingle Enzyme Nanoparticleen_US
dc.subjectStarving-Like Therapyen_US
dc.subjectTherapeutic Enzymeen_US
dc.titleAcrylamide-encapsulated glucose oxidase inhibits breast cancer cell viabilityen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
[1303829X - Turkish Journal of Biochemistry] Acrylamide-encapsulated glucose oxidase inhibits breast cancer cell viability (1).pdf
Boyut:
1.87 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: